



HHS Public Access

Author manuscript

Nat Chem Biol. Author manuscript; available in PMC 2023 November 01.

Published in final edited form as:

Nat Chem Biol. 2023 May ; 19(5): 633–640. doi:10.1038/s41589-022-01246-6.

Genome Mining for Unknown-Unknown Natural Products

Danielle A. Yee^{1,3}, Kanji Niwa¹, Bruno Perlatti^{2,3}, Mengbin Chen^{1,4}, Yuqing Li¹, Yi Tang^{1,2}

¹Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, CA 90095, USA

²Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA

³Present address: Hexagon Bio, Menlo Park, CA 94025, USA

⁴Present address: Department of Process Research and Development, Merck & Co., Inc., Rahway, NJ 07065, USA

Abstract

Genome mining of biosynthetic pathways with no identifiable core enzymes can lead to discovery of the so-called unknown (biosynthetic route)-unknown (molecular structure) natural products. In this work, we focused on a conserved fungal biosynthetic pathway (*ank*) that lacks a canonical core enzyme, and used heterologous expression to identify the associate natural product to be a highly modified cyclo-arginine-tyrosine dipeptide. Biochemical characterization of the *ank* pathway led to identification of a new arginine cyclodipeptide synthase (RCDPS), which was previously annotated as a hypothetical protein (HP) and has no sequence homology to nonribosomal peptide synthetase (NPRS) or bacterial cyclodipeptide synthase (CDPS). RCDPS homologs are widely encoded in fungal genomes and we showed other members of this family can synthesize diverse cyclo-arginine-Xaa dipeptides. Characterization of a cyclo-Arg-Trp (cRW) RCDPS showed the enzyme is aminoacyl-tRNA dependent, and represents the first report of such CDPS-like enzyme from fungi. Further characterization of the biosynthetic pathway anchored by the cRW synthase led to discovery of new compounds of which the structures would not have been predicted without knowledge of RCDPS function. Our work demonstrates the importance of examining unknown-unknown biosynthetic pathways towards discovering new scaffold-forming enzymes and expanding the chemical space of natural products.

Introduction

Genome mining has brought a renaissance to natural product discovery.^{1,2} Using homology-based functional predictions, bioinformatics algorithms can readily extract potential biosynthetic gene clusters (BGCs) from sequenced microbial genomes.^{3,4} It is estimated

yitang@ucla.edu .

Author contributions

D.A.Y. M.C. and Y.T. developed the hypothesis and designed the study. D.A.Y. and Y.L. performed in vivo and in vitro studies. D.A.Y. B.P. and K. N. purified and characterized the compounds. All authors analyzed and discussed the results and prepared the manuscript.

Competing interests

The authors declare no competing interests.

that over 1 million BGCs can be predicted from the current genome database, and can be mined for natural products using synthetic biology approaches.⁵ Anchored by canonical core enzymes such as polyketide synthases (PKSs), nonribosomal peptide synthetases (NRPSs), terpene synthases, and prenyltransferases, predicted BGCs that have no associated metabolites have been referred to as unknown cluster/known metabolite category (unknown-knowns).^{6,7} Despite the increased sophistication of microbial genome mining expeditions in the past few years,⁸ it remains highly challenging to identify and categorize potential BGCs that have no core enzymes or no proteins with sequence similarity to known core enzymes. Collectively referred to as the unknown cluster/unknown metabolite category (unknown-unknowns),⁶ these BGCs represent the true biosynthetic dark matter that are underexplored with respect to new structures and biological activities. Therefore, efforts aimed at identification and characterization of unknown-unknown BGCs and potentially new scaffold-forming enzymes are much needed.

In the search for new BGCs that have unknown metabolite category, one needs to deemphasize the presence of open reading frames (ORFs) in BGCs that are predicted to be known scaffold-building enzymes, and instead, search for clusters of ORFs that do not produce recognizable primary or secondary metabolites.^{9,10} For example, a BGC that contains a cluster of tailoring enzymes and no canonical core enzyme is a reasonable starting point, as evidenced by recent characterization of bacterial BGCs of altemicidin,¹⁰ fluopsin,¹¹ and guanitoxin.¹² These tailoring enzymes can include redox enzymes such as oxidoreductases,¹³ transferring enzymes such as methyl-, acetyl-, or glycosyl-transferases,¹⁴ and other enzymes that are found frequently in BGCs, such as PLP-dependent¹⁵ or ATP-grasp enzymes.^{16,17} In addition, the presence of ORFs that are designated as hypothetical proteins (HPs)¹⁸ or proteins predicted to have domains of unknown function (DUFs)¹⁹ is predictive of new enzymatic function. Bioinformatics identification of potential unknown-unknown clusters, followed by comparison of homologous BGCs in the genome database, can further highlight conserved ORFs and define cluster boundaries. In this work, we demonstrate such workflow to decode one family of unknown-unknown BGCs in filamentous fungi. We identified a new eukaryotic, tRNA-dependent dipeptide synthase that produces Arg-Xaa diketopiperazine (DKP)²⁰ compounds very rarely found in this family of natural products. This previously designated HP has no sequence homology to the known bacterial cyclodipeptide synthase (CDPS),^{21,22} and is widely conserved in fungi. Using this new core-forming enzyme as a genome mining beacon, new arginine-containing natural products were discovered.

Results and Discussion

Genome mining of the unknown-unknown *ank* cluster

To identify candidates for the aforementioned unknown-unknown BGCs, we started by searching for clusters that contain a PLP-dependent enzyme with sequence homology to cystathionine- γ -synthase. Previous work in both fungi and bacteria showed that homologs of these enzymes can catalyze PLP-dependent γ -replacement reactions using *O*-acyl-L-homoserine as substrate^{23, 24} to form C-N, C-C, and C-S bonds.^{15,25,26} We reasoned that BGCs without a core enzyme could utilize such enzymes to build molecular scaffolds.

Using our published algorithm that searches for BGCs that include and/or exclude specific enzymes,²⁷ we located one such unknown-unknown BGC from several different fungal species, including the *ank* cluster from *Aspergillus thermomutatus* (Fig. 1a and S1, Table S1). The encoded PLP-dependent enzyme AnkD shows 50% identity to the PLP-dependent enzymes CndF²³ and FlvA²⁸ (Table S1), which catalyze C-C bond formation. In addition to *ankD*, other conserved genes include those encoding a cytochrome P450 (*ankB*), a FAD-dependent monooxygenase (*ankC*), a NRPS-independent siderophore (NIS) synthetase (*ankE*), an *O*-methyltransferase (OMT) (*ankF*), and a homolog of the ATP-dependent glutathione synthetase (*ankG*). The *ankA* gene encodes a 518-aa hypothetical protein, which has no conserved domain or predicted function, and is also conserved among all clusters shown in Fig. 1a. Without a canonical core enzyme, no prediction of metabolite structure from this cluster can be made.

The genes *ankA-G* were expressed in the heterologous host *Aspergillus nidulans* A1145 EM ST for metabolite analysis.²⁹ This resulted in the emergence of several new metabolites, including **1** (molecular weight, MWT: 737), **3** (MWT: 622), **4** (MWT: 608) and **7** (MWT: 317) (Fig. 1b, ii). These compounds were purified and the structures were solved with NMR analysis. **1** with the highest MWT was elucidated to be a linear compound connecting cyclo-arginine-dehydrotyrosine dipeptide, homoserine, citrate and aspartate (Fig. S25-S29, Table S7). A compound database search showed that **1** (named here NK13650 C) is the *O*-methylated version of the p300-histone acetyltransferase (HAT) inhibitor **2** (NK13650 A).³⁰ **3** (named here NK13650 D) was solved to be the precursor of **1** prior to attachment of the L-Asp residue (Fig. S33-S37, Table S9), while **4** corresponded to the *O*-desmethylated version of **3** (NK13650 B, Fig. S43-S45, Table S11).³⁰ We also detected and isolated an ornithine version of **3** from the extract (**3b**), which we propose to derive from **3** via the activities of the host arginase³¹ (Fig. S10, S38-S42, Table S10). Lastly from this strain, NMR analysis of **7** confirmed the compound to be cyclo-Arg-dehydro-Tyr (Fig. S94) with the *Z* olefin configuration.³²

The structures of these compounds suggest **1** is biosynthesized in a step-wise fashion starting with the cyclo-Arg-Tyr diketopiperazine (cRY) **8**. To assign functions to the enzymes encoded in the gene cluster, individual genes were removed stepwise from the fully reconstituted pathway, followed by metabolite detection and structural analysis. We first assigned the *O*-methyltransferase *ankF* to be responsible for methylation of the C17 phenol group. Coexpression of the entire biosynthetic cassette except *ankF* led to the formation of **4**, as well as the expected emergence of **2** (NK13650 A, MWT: 723) (Fig. S30-S32, Table S8),³⁰ confirming the role of AnkF (Fig. 1b, iv). The NMR data and optical rotation measurement of **2** matched those in the previous publication,³⁰ and led to the complete assignment of stereochemistries of the different building blocks in **2**, as well as those in **1**. In parallel, comparing the structures of **1** and **3** suggests that amidation of **3** with L-Asp is likely the last step. This could be catalyzed by the predicted ATP-grasp enzyme AnkG, which was initially predicted as a hypothetical protein but displayed the closest secondary structure homology³³ to glutathione synthetase, which produces ADP and P_i during catalysis.³⁴ Removal of *ankG* from the pathway led to disappearance of **1** and

predominant accumulation of **3** (Fig 1b, iii). The accumulation of both **2** and **4** in the strain without AnkF suggests AnkG can also use **4** as a substrate.

The next enzyme involved in the biosynthesis of **4** is likely the predicted NIS homolog AnKE. NIS homologs are predominantly found in bacteria and are involved in the biosynthesis of citrate-containing siderophores, such as staphyloferrin A and aerobactin.^{35,36} Typically, one carboxylate of citrate is adenylated followed by amide bond formation with amine nucleophiles.³⁷ We propose that AnKE has an analogous function to ligate citrate to the precursor **5**. Indeed, expression of the remaining genes (*ankABCD*) without *ankE* led to the disappearance of **4** and emergence of **5** (MWT: 434) and **6** (MWT: 333) (Fig. 1b, v). Characterization of **5** by NMR confirmed the proposed structure, in which the side chain of L-homoserine is attached to the DKP via an aryl ether linkage (Fig. S46-S50, Table S12). We also isolated and characterized **6**, which is the precursor to **5** without the L-homoserine attachment (Fig. S51-S55, Table S13). The conversion of **6** to **5** requires expression of the PLP-dependent enzyme AnkD, as expression of *ankABC* only resulted in formation of **6** (Fig. S11, iii). Recombinant AnkD purified from *E. coli* (Fig. S9) was confirmed to convert **6** to **5** in an *O*-acetyl-L-homoserine dependent fashion (Fig. S12). This is the first confirmed example of C-O bond formation through γ -substitution by a PLP-dependent enzyme, and the mechanism is shown in Fig. S5.

The remaining unassigned enzymes AnkA (HP), AnkB (P450) and AnkC (FMO) are involved in the early steps of the pathway that form **6**. Expression of AnkA alone in *A. nidulans* led to the emergence of a polar compound **8** (Fig. S13, ii), which was structurally verified to be cRY dipeptide (Fig. S95).³⁸ Expression of AnkA in *Saccharomyces cerevisiae* JHY651³⁹ also led to the accumulation of **8** (Fig. S14). Expression of AnkA and AnkB afforded the previously characterized dehydro-cyclodipeptide **7** (Fig. S11, iv), which indicates the P450 enzyme is responsible for desaturation, likely through hydroxylation of the benzylic position in **8** followed by dehydration.^{40,41} Finally, AnkC is assigned as the hydroxylase that installs the *m*-OH in **6**, through a canonical flavin-dependent aromatic hydroxylation mechanism.⁴²

Collectively, reconstitution of the biosynthesis of **1** from the *ank* BGC shows that a bioactive natural product with considerable structural complexity can be generated without a *bona fide* core enzyme. Primary cellular metabolites, including L-Arg, L-Tyr, L-Asp, L-homoserine, and citrate were combined in sequential order to furnish the final product **1**. This finding supports additional efforts to mine such unknown-unknown BGCs for new natural products.

AnkA and Homolog are Cyclo-Arginine-Xaa Dipeptide Synthases

The most unexpected finding in the biosynthesis of **1** is that AnkA is responsible for formation of the cyclodipeptide **8**. Given that the remaining pathway builds on **8**, AnkA can be considered as the scaffold generating enzyme. Cyclodipeptides are generally formed via two routes: i) an NRPS-dependent pathway present in both bacteria⁴³ and fungi,^{44,45} and ii) a tRNA-dependent pathway catalyzed by cyclodipeptide synthase (CDPS) only found in bacteria.^{21,22} AnkA is a 518-residue protein that has no predicted function, no characterized sequence homolog, and no structural homolog detected through Phyre2.³³

We searched for Anka homologs that may catalyze formation of other cyclodipeptides. A tBLASTn search using *ankA* as query against the JGI ascomycete genome database, NCBI nucleotide collection, as well as in-house fungal genome sequences identified more than 100 hits for homologs with greater than 20% identity to *ankA* (Table S6). Selected sequences were used to generate a phylogenetic tree using MAFFT software (Fig. 2).⁴⁶ Analysis of the genes surrounding the homologs showed that while some are standalone with no predicted tailoring enzymes nearby, others are flanked by diverse tailoring enzymes as seen in the *ank* cluster (Fig. S3). Six of these homologs were chosen for functional analysis, including AnoA from *Aspergillus nomius*; AvaA from *A. versicolor*; PthA from *Penicillium thymicola*; AteA from *A. terreus*; AmaA from *Apiospora montagnei*; and EshA from *Eupenicillium shearii*. A sequence alignment of these to Anka can be found in Fig. S4, which showed limited sequence homology.

Each of the Anka homologs was expressed in *A. nidulans* followed by metabolite analysis (Fig. S13). We observed a variety of arginine containing DKPs, including: cyclo-Arg-Asp (cRD, **9**) from PthA (Fig. S56-S60, Table S14); cyclo-Arg-Glu (cRE, **10**) from AteA (Fig. S61-S65, Table S15); cyclo-Arg-Pro (cRP, **11**)⁴⁷ from AmaA (Fig. S96); cyclo-Arg-Leu (cRL, **12**)⁴⁸ from EshA (Fig. S97); and cyclo-Arg-Trp (cRW, **13**)⁴⁹ from both AvaA and AnoA (Fig. S66-S67, Table S16). Notably, **11** is the only example of an arginine containing DKP produced by a bacterial CDPS from *Lysobacter antibioticus*.⁵⁰ Halogenated and ring-modified variants of cRP have been previously isolated from marine sponges,^{51,52} and the sequence of AmaA could be used to mine the metagenome for the BGCs of these derivatives. The stereochemistry of **13** was confirmed by Marfey's analysis and NMR comparison to synthetic cyclo-L-Arg-L-Trp⁴⁹ (Fig. S20, Table S16). Therefore, it is evident that all active Anka homologs utilize arginine as one of the amino acid building blocks, while the second amino acid can vary. With the exception of cRP,⁵⁰ arginine-containing DKPs have been conspicuously absent from microbial metabolomes. Our discovery of the Anka family of enzymes, which we rename here to be arginine-containing cyclodipeptide synthases (RCDPSs), shows Nature can indeed synthesize a variety of such guanidine-containing DKPs. Based on the product structures and phylogenetic relationship shown in Fig. 2, each subclade has different substrate specificity for the second amino acid (D, E, P, W, L, Y). Exploring the biosynthetic products of RCDPSs from other clades should therefore give rise to additional arginine-containing DKPs.

RCDPSs are tRNA-dependent cyclodipeptide synthases

To study the mechanism of RCDPSs, we attempted to express the homologs from Fig. 2 from either yeast or *E. coli* as soluble proteins. While several of these enzymes functioned in yeast to produce the expected cyclodipeptide (Fig. S14-S15), the cRW **13**-producing AvaA functioned in both *E. coli* and yeast robustly (Fig. S16 and S18). As a result, subsequent biochemical studies focused on AvaA as a representative member.

We first assayed the activity of AvaA in lysate from the yeast expression strain. Trp-(*indole*)-d₅ was added to the lysate to distinguish newly synthesized cRW-d₅ from those produced during yeast culturing. The **13**-d₅ product (MWT: 348) was observed from the lysate (Fig. 3a), in contrast to the negative control in which no Trp-d₅ was added. Given that AvaA

bears no similarity to NRPS, we started off by determining if the formation of **13** is RNA-dependent. Treating the lysate with RNase A prior to substrate addition completely abolished **13**-d₅ formation. In lysates treated with RNase A followed by addition of the RNase A inhibitor RNasin, formation of **13**-d₅ was only observed after addition of total yeast RNA, indicating the reaction is RNA-dependent (Fig. 3a). In assays with lysate that was first desalted to remove small molecules and salts, addition of ATP and MgCl₂, which are necessary for aminoacyl-tRNA synthetase function,^{53,54} was required for product formation (Fig. S17). These observations are consistent with AvaA being a RNA-dependent enzyme, functionally analogous to bacterial CDPSs.^{55,56}

We then performed *in vitro* reactions with recombinant AvaA expressed and purified from *E. coli* (Fig. S9). The yeast arginine-tRNA synthetase (ArgRS, YDR341C)⁵⁷ and tryptophan-tRNA synthetase (TrpRS, YOL097C)⁵⁸ were also expressed and purified from *E. coli* (Fig. S9). Production of **13**-d₅ was observed in the complete reconstitution that contained AvaA, ArgRS, TrpRS, L-Trp-d₅, L-Arg, deacylated total yeast RNA, ATP, and MgCl₂ (Fig. 3b). Omitting ArgRS or TrpRS, as well as MgCl₂ or ATP, completely abolished cyclodipeptide formation, consistent with the requirement of aminoacylated tRNA for AvaA function. Omission of L-Trp-d₅ abolished product formation, whereas exclusion of L-Arg resulted in trace amounts of **13**-d₅ being formed. This background activity may be due to our inability to completely deacylate L-Arg-tRNA in the total RNA pool. To confirm tRNA is required, we isolated tRNA from yeast total RNA using PAGE electrophoresis (Fig. S22); followed by confirmation of isolated tRNA through RT-PCR (Fig. S24). Gratifyingly, replacement of total RNA with purified tRNA in the complete reconstitution assay above supported formation of **13** (Fig. 3c). In contrast, addition of other purified RNA fractions from PAGE, including the 5S RNA and degraded RNA front, did not support **13** synthesis (Fig. S23). Collectively, these biochemical assays confirmed AvaA and by inference, other members of the RCDPS family are tRNA-dependent cyclodipeptide synthases with the mechanism shown in Fig. S6.

CDPSs, including the well-characterized AlbC (cLF synthase, PDB: 4Q24),⁵⁶ share a conserved catalytic triad of Ser, Glu and Tyr residues, of which Ser forms the covalent aminoacyl adduct followed by intramolecular DKP cyclization.⁵⁶ Alignment of the six functionally verified RCDPS in Fig. 2 led to identification of only few conserved residues, including E432 and Y515, of which E432 is part of a D₄₂₈D₄₂₉XXE₄₃₂ motif (Fig. S4). To investigate the functions of these residues in RCDPS, we expressed single-residue mutants of AvaA in yeast and evaluated cRW production. Both E432A and Y515A mutations led to complete loss of cyclodipeptide formation (Fig. S18, v-x). Yeast expressing Y515F mutation also significantly decreased the formation of **13** by 89% (Fig. S18, xi-xiii.). To gain more insight into RCDPS catalysis, using the AlphaFold⁵⁹ structural prediction tool, parts of the predicted RCDPS (518 aa) structure showed a striking resemblance (RMSD 3 Å) to that of the much smaller AlbC (239 aa), with 32% coverage of AvaA (Fig. 3d and S8). The core of RCDPS adopts a Rossmann fold, which is observed for bacterial CDPSs.⁶⁰ Structural comparison revealed that a conserved cysteine residue in RCDPS (C193 in AvaA) aligns with the active site serine (S37) in AlbC, and conserved D428 and D429 that are part of the DDXXE motif are predicted to be at the same location as the general base Y202 in

AlbC (Fig. 3d, S8d). In addition, Y392 in AvaA is predicted to be at the same position in the active site as E182 in AlbC, which is the general base that deprotonate the positively charged amino group of the acyl acceptor for the first amide bond formation (Fig. 3d, S8e). Introducing C193A, C193S or C193T mutations completely abolished AvaA activity (Fig. 3e; S19a). In addition, D428A, D429A, Y392A and Y392F mutations also abolished AvaA activity (Fig. 3e; S19). Overall, while the full structure of RCDPS will be needed to assign the roles to these residues, C193, DDXXE, Y392 and Y515 are important for the catalytic activity of RCDPSs, and conservation of these residues should be a criterion when mining for additional RCDPS homologs. A proposed role of these residues is shown in Fig. S8.

Genome mining of *ava* cluster led to new natural products

To determine if the cRW cyclodipeptide **13** can be modified into more elaborate natural products, we performed coexpression of nearby genes from the *A. versicolor* cluster (Fig. 4a). Immediately flanking *avaA* is *avaB* that encodes an FMO with 28% identity to dimethylaniline monooxygenase; *avaC* that encodes a kynurenine formamidase (KFA), and *avaD* that encodes a protein with 38% identity to Gcn5-related *N*-acetyltransferases (GNAT)⁶¹ (Fig. 4a). Other genes nearby encode additional tailoring enzymes, including five P450s, a beta-lactamase, and a dioxygenase, etc. (Table S2). Most of these genes are conserved in homologous clusters from three other fungal species, suggesting their involvement in the pathway (Fig. S2). However, given the size of the entire cluster (31 kB) poses challenges for heterologous reconstitution, we chose to first examine the immediate genes flanking *avaA* as shown in Fig. 4a.

Coexpression of *avaA-D* in *A. nidulans* resulted in a number of compounds **14–18** (Fig. S21), which were isolated and structurally characterized (Fig. 4b). Compound **14** is a pyrroloindole DKP with a fused 6/5/5/6 ring system (Fig. S68-S72, Table S17). **15** was determined to be a derivative of **14** upon hydrolysis of the guanidine group (Fig. S73-S77, Table S18), which could be catalyzed by *A. nidulans* arginase.³¹ We propose **14** is derived from AvaB catalyzed epoxidation of the indole ring in **13** to **19**, followed by epoxide opening to generate the hydroxyiminium **20** that can be captured intramolecularly as a shunt pathway by the amide nitrogen (Fig. S7).^{62,63} On the other hand, the structures of **16** and **17** revealed cleavage of the indole ring, followed by oxidative rearrangements. **16** is the cyclo-Arg-kynurenine dipeptide (Fig. S78-S82, Table S19), while **17** contains a 10 ϵ conjugated benzene-isoxazole bicyclic anthranil ring structure (Fig. S83-S87, Table S20). Anthranils have emerged as privileged synthons to construct a diverse array of C-N bonds.⁶⁴ To the best of our knowledge, this is the first report of an anthranil functional group found in natural products. We propose AvaB is a multifunctional flavoenzyme that is responsible for generating the cyclo-Arg-formylkynurenine DKP **21**, which can be deformed by AvaC to give **16** (Fig. S7). An additional *N*-oxidation of **16** by AvaB followed by cyclization and dehydration gives **17**. Lastly, **18** was solved by NMR analysis to be a derivative of **17** following *N*-acetylation of the guanidine group (Fig. S88-S93, Table S21). Stepwise reconstitution confirmed *N*-acetylation is catalyzed by the Gcn5 homolog AvaD (Fig. S21). Although a handful of natural products containing acetylated arginine have been isolated previously,^{65,66} this is the first identification of an arginine *N*-acetyltransferase. Additional genes in the *ava* cluster were introduced into the heterologous host. However,

no modification of the products could be detected. The roles of these enzymes in the *ava* pathway are under investigation.

Conclusions

The first discovery of aminoacyl-tRNA-dependent natural product biosynthesis was made in 2008.⁶⁷ Since then, an increasing number of such enzymes have been identified from bacteria and studied.⁶⁰ Leveraging aminoacyl-tRNA in natural product biosynthesis blurs the line between primary and secondary metabolism, exemplifying Nature's expansive toolkit to promote molecular diversity. Our discovery of a new family of enzymes termed RCDPS fills in the blank of biosynthetic machineries constructing Arg-containing cyclodipeptides, across both prokaryotic and eukaryotic kingdoms. The RCDPS constitutes a new class of core genes in natural product biosynthesis, and together with the additional tailoring enzymes found here, can broaden the scope of future genome mining endeavors for novel natural products. Our work demonstrates the power of bioinformatics-guided genome mining in unlocking the vast biosynthetic potential of unknown-unknown natural product BGCs in microbial genomes.

METHODS

1. Strains and culture conditions

Aspergillus thermomutatus, *Aspergillus versicolor* dI-29, *Apiospora montagnei*, *Aspergillus terreus*, *Penicillium thymicola*, *Aspergillus nomius*, and *Penicillium subrubescens* were grown on PDA (potato dextrose agar, BD) at 28 °C for 3 days for cell proliferation or in liquid PDB medium (PDA medium without agar) for isolation of genomic DNA. *Aspergillus nidulans* A1145 ST EM⁶⁸ was grown at 28 °C on CD medium (1 L: 10 g of glucose, 50 mL of 20X nitrate salts, 1 mL of trace elements, pH 6.5, and 20 g/L of agar for solid cultivation) for heterologous expression of the gene cluster, compound production, and RNA extraction. For preparation of 20X nitrate salts, 120 g of NaNO₃, 10.4 g of KCl, 10.4 g of MgSO₄•7H₂O, 30.4 g of KH₂PO₄ were dissolved in 1 L of double distilled water. For preparation of the trace element solution, 2.20 g of ZnSO₄•7H₂O, 1.10 g of H₃BO₃, 0.50 g of MnCl₂•4H₂O, 0.16 g of FeSO₄•7H₂O, 0.16 g of CoCl₂•5H₂O, 0.16 g of CuSO₄•5H₂O, and 0.11 g of (NH₄)₆Mo₇O₂₄•4H₂O were dissolved in 100 mL of double-distilled water, and the pH was adjusted to 6.5.² All *Escherichia coli* strains were cultured in LB media at 37 °C. Yeast strains were cultured in YPD media (yeast extract 1%, peptone 2%, glucose 2%) at 28 °C.

2. General DNA manipulation techniques

E. coli TOP10 was used for cloning, following standard recombinant DNA techniques. DNA restriction enzymes were used as recommended by the manufacturer (New England Biolabs, NEB). PCR reactions were performed using Q5 High-Fidelity DNA Polymerase (NEB), Phusion High-Fidelity DNA Polymerase (NEB), and PFX High-Fidelity DNA Polymerase (Invitrogen). The gene-specific primers are listed in Table S5. PCR products were confirmed by DNA sequencing. *E. coli* BL21(DE3) (Novagen) was used for protein

expression. The *Saccharomyces cerevisiae* strain JHY651³⁹ was used as the yeast host for *in vivo* homologous recombination to construct the *A. nidulans* expression plasmids.

For isolation of RNA from *A. nidulans* transformants containing the *ank* gene cluster, the strains were grown on CD agar for 3 days at 28 °C. The RNA extraction was performed using RiboPure™ Yeast RNA Isolation Kit (Ambion) following the manufacturer's instructions. Residual genomic DNA in the extracts was digested by DNase I (2 U/μL) (Invitrogen) at 37 °C for 4 hours. SuperScript III First-Strand Synthesis System (Invitrogen) was used for cDNA synthesis with oligo-dT primers following directions from the user manual.

3. Heterologous expression of the *ank* and *ava* gene clusters as well as AnkA homologs from *A. montagnei*, *A. terreus*, *P. thymicola*, *A. nomius*, and *E. shearii* in *A. nidulans*

To construct plasmids for heterologous expression in *A. nidulans* A1145, the plasmids pYTU, pYTP, and pYTR⁶⁹ with auxotrophic markers for uracil (*pyrG*), pyridoxine (*pyroA*), and riboflavin (*riboB*), respectively, were used as backbones to insert genes. Genes from the *ank* and *ava* gene clusters as well as AnkA homologs from *A. montagnei*, *A. terreus*, *P. thymicola*, *A. nomius*, and *E. shearii* and their native terminators were amplified by PCR with overhang primers using the genomic DNA (gDNA) from the native hosts as the template. Constitutive *gpdA* promoters from *A. niger* (*gpdAp*), *Penicillium oxalicum* (PO*gpdAp*), and *Penicillium expansum* (PE*gpdAp*) as well as *coxAp* from *A. niger* were amplified by PCR. pYTP and pYTR were digested with PacI/NotI and pYTU was digested with PshAI/NotI. The overlapping DNA fragments and their corresponding digested vectors were co-transformed into *S. cerevisiae* JHY651³⁹ to assemble the expression plasmids *in vivo* by yeast homologous recombination. The plasmids were extracted from yeast using Zymoprep™ Yeast Plasmid Miniprep I (Zymo Inc. USA), and transformed into *E. coli* TOP10 by electroporation to isolate single plasmids. After extraction from *E. coli*, the plasmids were sequenced to confirm correct assembly.

To prepare protoplasts, *A. nidulans* A1145 ST EM⁶⁸ was initially grown on CD agar plates supplemented with 10 mM of uridine, 5 mM of uracil, 0.5 μg/ml of pyridoxine HCl and 2.5 μg/ml of riboflavin at 30 °C for 5 days. Fresh spores of *A. nidulans* A1145 were inoculated into 50 mL of liquid CD media in a 250-mL flask and germinated at 30 °C, 250 rpm for 16 h. Mycelia were harvested by centrifugation at 3,500 rpm for 10 min and washed with 10 mL of osmotic buffer (1.2 M of MgSO₄, 10 mM of sodium phosphate, pH 5.8). The mycelia were transferred into 10 mL of osmotic buffer containing 20 mg of lysing enzymes from *Trichoderma* and 15 mg of Yatalase in a 1250-mL flask. The cells were digested for 6–8 hours at 30 °C, 80 rpm and were then poured through a sterile cell strainer (Fisher, Cat No. 22363547) into a sterile 50 mL Falcon tube. The filtrate containing the digested cells was centrifuged at 4300 x *g* for 20 min at 4 °C. The supernatant was decanted and the pellet was washed with 10 mL of STC buffer (1.2 M of sorbitol, 10 mM of CaCl₂, 10 mM of Tris-HCl, pH 7.5). The protoplasts were then resuspended in 1 mL of STC buffer.

For each transformation, plasmids were added to 100 μl of the *A. nidulans* A1145 protoplast suspension prepared above, and the mixture was incubated for 60 min on ice. Then 600 μl of PEG solution (60% PEG, 50 mM of calcium chloride, and 50 mM of Tris-HCl, pH 7.5)

was added to the protoplast mixture, followed by additional incubation at room temperature for 20 min. The mixture was dropped on CD sorbitol agar plates (CD solid medium with 1.2 M of sorbitol and the appropriate supplements: 10 mM of uridine, 5 mM of uracil, 0.5 µg/mL of pyridoxine HCl, and/or 2.5 µg/mL of riboflavin according to the markers in the transformed plasmids) and incubated at 37 °C for 2–3 days.

4. Chemical analysis and compound isolation.

For small scale metabolite analysis in *A. nidulans*, transformants were grown on CD agar for 2–6 days at 28 °C and then extracted with methanol. *A. nidulans* strains expressing AvaABD, AvaA-D, and AvaACD were grown on CD agar for 2 days at 28 °C and then extracted with acetone. For small scale analysis of production of compounds **8**, **11** and **13** in yeast, *S. cerevisiae* JHY651 strains expressing AnkaA, AmaA, and AvaA (wildtype and mutants) were inoculated in 1 mL of dropout media for 24 hours. 100 µL of starter culture was used to inoculate 3 mL of YPD. The cells were grown at 28 °C, 250 rpm for 48 hours and the cell pellets were extracted with acetone for **8** and **11** and methanol for **13**, respectively. The organic phases were dried and dissolved in 50% water 50% methanol for analysis. LC-MS analyses were performed on a Shimadzu 2020 EV LC-MS with a reverse-phase column (Phenomenex Kinetex, C18, 1.7 µm, 100 Å, 2.1 × 100 mm) using positive- and negative-mode electrospray ionization with a linear gradient of 5–95% acetonitrile-H₂O (containing 0.1% formic acid) in 15 min followed by 95% acetonitrile for 3 min with a flow rate of 0.3 ml/min. QTOF analysis was performed on an Agilent Quadrupole Time of Flight LC/MS (6545 LC/Q-TOF) with a reverse-phase column (Agilent Poroshell, 120 EC-C18, 2.7 µm, 3.0 × 50 mm) using positive-mode electrospray ionization with a linear gradient of 1–95% acetonitrile-H₂O (containing 0.1% formic acid) in 9 min followed by 95% acetonitrile for 3 min with a flow rate of 0.6 mL/min.

For isolation of **3** and **3b**, an *A. nidulans* transformant expressing AnkaA-F was grown on 4 L of solid CD media for 5 days at 28 °C and then extracted with methanol. For isolation of **4**, an *A. nidulans* transformant expressing AnkaA-E was grown on 4 L of solid CD media for 5 days at 28 °C and then extracted with methanol. For isolation of **2**, an *A. nidulans* transformant expressing AnkaABCDEG was grown on 4 L of solid CD media for 3 days at 28 °C and then extracted with methanol. For isolation of **1**, an *A. nidulans* transformant expressing AnkaA-G was grown on 4 L of solid CD media for 3 days at 28 °C and then extracted with methanol. The extracts were concentrated and the methanol was removed by a rotary evaporator. The pH of the aqueous extracts was lowered to 4, and the extracts were mixed with Diaion[®] HP-20 resin for 1 hour. The resin mixtures were then poured through a column, and the flowthrough was discarded. The resin was washed with water and 25% methanol with 0.1% formic acid. The compounds were eluted from the resin with 50% methanol. The eluent was concentrated and extracted with chloroform to remove impurities. The resulting aqueous extracts were used for purification by HPLC with a semi-preparative reverse-phase column (Cosmosil 5C18-AR-II, 10ID x 250 mm) with water (A) and methanol (B) with 0.1% formic acid using a gradient of 0–20 min 25% B; 25–32 min 100% B; 32–39 min 25% B. For **3b**, fractions containing the target compound were combined and further purified by HPLC with a semi-preparative reverse-phase column (Kinetex 5 µm C18 100 Å, 250 × 10.0 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient

of 0–5 min 5% B; 5–83 min 5–10% B; 83–90 min 100% B; 90–97 min 5% B. For **2** and **4**, fractions containing the target compounds were combined and further purified by HPLC with a semi-preparative reverse-phase column (Cosmosil 5C18-MS-II, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–60 min 17% B; 60–67 min 100% B; 67–74 min 17% B. For **1**, fractions containing the target compound were combined and further purified by HPLC with a semi-preparative reverse-phase column (Kinetex 5 μ m C18 100 Å, 250 x 10.0 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 5% B; 5–85 min 5–10% B; 85–92 min 100% B; 92–99 min 5% B.

For isolation of **7**, **8**, and **12**, *A. nidulans* transformants expressing AnkA and AnkAB, respectively, were grown on 4 L of solid CD media for 4 days at 28 °C and then extracted with acetone. For isolation of **11**, *amaA* was cloned into the yeast expression vector XW55⁴ through yeast homologous recombination. In this plasmid, expression of *amaA* was under the control of the *ADH2* promoter. *S. cerevisiae* JHY651³⁹ expressing AmaA was inoculated in 80 mL of dropout media for 24 hours. The starter culture was used to inoculate 4 L of YPD, and the cells were shaken at 28 °C, 250 rpm for 48 hours. The cell pellet was harvested by centrifugation and extracted with acetone. The crude extracts were absorbed with 3 g of Celite, which was purified with the CombiFlash system (Teledyne) using a 100 g HP C18 column (RediSepR_f) and reverse phase gradient elution with water (A) and methanol (B) using a gradient of 0–5 min 5% B; 5–125 min 5–100% B; 125–135 min 100% B. For compound **12**, acetonitrile was used instead of methanol during CombiFlash purification. For compound **7**, fractions containing the target compound were subject to purification by HPLC with a semi-preparative reverse-phase column (Cosmosil 5C18-AR-II, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–17 min 20% B; 17–24 min 100% B; 24–31 min 20% B. A second HPLC step was performed with a semi-preparative reverse-phase column (Cosmosil PBr, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 0% B; 5–65 min 0–20% B; 65–72 min 100% B; 72–79 min 0% B. For **12**, fractions containing the target compound from the CombiFlash were combined and purified by HPLC with a semi-preparative reverse-phase column (Cosmosil 5C18-AR-II, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 5% B; 5–45 min 5–10% B; 45–54 min 100% B; 54–63 min 5% B. For **11**, fractions containing the target compound from the CombiFlash were combined and purified by HPLC with a semi-preparative reverse-phase column (Cosmosil PBr, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 5% B; 5–25 min 5–95% B; 25–32 min 95% B; 32–39 min 5% B.

For isolation of **9** and **10**, *A. nidulans* transformants expressing PthA and AteA, respectively, were grown on 4 L of solid CD media for 4 days at 28 °C and then extracted with methanol. The crude extracts were absorbed with 3 g of Celite, which was purified with the CombiFlash system (Teledyne) using a 100 g HP C18 column (RediSepR_f) and reverse phase gradient elution with water (A) and methanol (B) using a gradient of 0–40 min 5% B; 40–55 min 100% B. For **9**, fractions containing the target compound were combined and purified by HPLC with a semi-preparative reverse-phase column (Cosmosil PBr, 10ID x 250

mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 0% B; 5–20 min 0–1% B; 20–27 min 100% B; 27–34 min 0% B. The compound was purified with two more rounds of HPLC with the same column and solvent system using a gradient of 0–20 min 0% B; 20–27 min 100% B; 27–34 min 0% B. For **10**, fractions containing the target compound from the CombiFlash were combined and purified by HPLC with a semi-preparative reverse-phase column (Cosmosil 5C18-AR-II, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–8 min 5% B; 8–15 min 100% B; 15–22 min 5% B. The compound was further purified by HPLC with a semi-preparative reverse-phase column (Cosmosil PBr, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 0% B; 5–20 min 0–4% B; 20–27 min 100% B; 27–34 min 0% B.

For isolation of **5** and **6**, an *A. nidulans* transformant expressing AnkABCDF was grown on 4 L of solid CD media for 3 days at 28 °C and then extracted with methanol. The extracts were concentrated and the methanol was removed by a rotary evaporator. The pH of the aqueous extracts was lowered to 4, and the extracts were mixed with Diaion® HP-20 resin for 1 hour. The resin mixture was then poured through a column, and the flowthrough was discarded. The resin was washed with water and 10% methanol with 0.1% formic acid. The compounds were eluted from the resin with 30% methanol. The eluent was concentrated and extracted with chloroform to remove impurities. The resulting aqueous extract was used for purification by HPLC with a semi-preparative reverse-phase column (Cosmosil 5C18-AR-II, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 5% B; 5–40 min 5–13.8% B; 40–47 min 100% B; 47–54 min 5% B. Fractions containing **6** were further purified by HPLC with a semi-preparative reverse-phase column (Cosmosil PBr, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 2% B; 5–105 min 2–12% B; 105–112 min 100% B; 112–117 min 2% B. Fractions containing **5** were further purified by HPLC with a semi-preparative reverse-phase column (Cosmosil PBr, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 2% B; 5–50 min 2–13.7% B; 50–57 min 100% B; 57–64 min 2% B.

For isolation of **13**, an *A. nidulans* transformant expressing AvaA was grown on 4 L of solid CD media for 4 days at 28 °C and then extracted with methanol. For isolation of **14** and **15**, an *A. nidulans* transformant expressing AvaABC was grown on 4 L of solid CD media for 3 and 6 days, respectively, at 28 °C and then extracted with methanol. For isolation of **16** and **17**, an *A. nidulans* transformant expressing AvaA-D was grown on 4 L of solid CD media for 3 days at 28 °C and then extracted with methanol. The extracts were concentrated by a rotary evaporator. The aqueous extracts were mixed with Diaion® HP-20 resin for 1 hour. The resin mixtures were then poured through a column, and the flowthrough was discarded. The resin was washed with water and 25% and 50% methanol. The compounds were eluted from the resin with 75% methanol. The eluent was concentrated and extracted with chloroform to remove impurities. The resulting aqueous extracts were used for purification by HPLC with a semi-preparative reverse-phase column (Cosmosil 5C18-AR-II, 10ID x 250 mm) with water (A) and methanol (B) with 0.1% formic acid using a gradient of 0–5 min 5% B; 5–45 min 5–19% B; 45–52 min 100% B; 52–59 min 5% B.

For **13** and **14**, fractions containing the target compounds were further purified by HPLC with a semi-preparative reverse-phase column (Cosmosil PBr, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 6% B; 5–65 min 6–13% B; 65–72 min 100% B; 72–79 min 6% B. For **15**, fractions containing the target compound were purified by HPLC with a semi-preparative reverse-phase column (Cosmosil 5C18-AR-II, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–25 min 5% B; 25–32 min 100% B; 32–39 min 5% B. For **16**, fractions containing the target compound were further purified by HPLC with a semi-preparative reverse-phase column (Cosmosil PBr, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 2% B; 5–65 min 2–20% B; 65–72 min 100% B; 72–79 min 2% B. For **17**, fractions containing the target compound were further purified by HPLC with a semi-preparative reverse-phase column (Cosmosil PBr, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 2% B; 5–65 min 2–14% B; 65–72 min 100% B; 72–79 min 2% B.

The stereochemistry of **13** was determined by Marfey's analysis and proton NMR spectroscopy. The proton NMR spectra of **13** corresponded to that of L-L or D-D cyclo-Arg-Trp.⁴⁹ For Marfey's analysis, 0.2 mg of **13** was hydrolyzed with 500 μ L of 6 M HCl with the addition of 1% beta-mercaptoethanol⁷⁰ to prevent degradation of tryptophan for 1 hour. Standards of L-Trp and D-Trp and hydrolyzed **13** were derivatized with Marfey's reagent.⁷¹ The samples were analyzed on the QTOF (Fig. S20), indicating **13** contains L-Trp. Together, we concluded **13** is composed of L-Arg and L-Trp.

For isolation of **18**, an *A. nidulans* transformant expressing AvaA-D was grown on 8 L of solid CD media for 2 days at 28 °C and then extracted with acetone. The extracts were concentrated by a rotary evaporator. The aqueous extract was mixed with Diaion[®] HP-20 resin for 1 hour. The resin mixture was then poured through a column, and the flowthrough was discarded. The resin was washed with water and the target compound was eluted with 25% acetonitrile. The eluent was concentrated and extracted with chloroform to remove impurities. The resulting aqueous extract was used for purification by HPLC with a semi-preparative reverse-phase column (Cosmosil 5C18-AR-II, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 5% B; 5–45 min 5–15% B; 45–52 min 100% B; 52–59 min 5% B. Fractions containing the target compound were further purified by HPLC with a semi-preparative reverse-phase column (Cosmosil PBr, 10ID x 250 mm) with water (A) and acetonitrile (B) with 0.1% formic acid using a gradient of 0–5 min 1% B; 5–125 min 1–15% B; 125–132 min 100% B; 132–139 min 1% B. To determine the position of the acetyl group in **18**, the ROESY correlation between H13 to H19 indicated the guanidine group is connected to C13. The HMBC correlation from H17 to C16 and chemical shift of C16 (172.6 ppm) showed the presence of an acetyl group. ROESY correlations between H14 and H18 and between H17 and H18 indicated the acetyl group is connected to the guanidine group.

NMR spectra were obtained with a Bruker AV500 spectrometer with a 5-mm dual cryoprobe at the UCLA Molecular Instrumentation Center (¹H 500 MHz, ¹³C 125 MHz). For compounds **1**, **3**, **3b**, **4**, **5**, **6**, **12**, **16**, and **17**, NMR spectra were measured in D₂O with the addition of 0.5% TFA-*d* to increase compound solubility. For compounds **2** and **4**, NMR

spectra were measured in DMSO- d_6 with 0.5% TFA- d . The NMR spectra of compounds **7** and **18** were measured in DMSO- d_6 . The NMR spectra of compounds **8** and **13** were measured in CD₃OD. The NMR spectra of compounds **9**, **10**, **14**, and **15** were measured in D₂O. Optical rotations were measured on a Rudolph Research Analytical Autopol III Automatic Polarimeter.

5. Preparation of yeast lysates containing AvaA and *in vitro* lysate assays

AvaA was cloned into the yeast expression vector XW55⁷² through yeast homologous recombination. In this plasmid, expression of *avaA* was under the control of the *ADH2* promoter. Overexpression of AvaA was performed as follows:⁷³ the yeast strain JHY651³⁹ harboring the expression plasmid was grown overnight in 3 × 1 mL cultures of uracil dropout medium at 28 °C. The starter culture was used to inoculate 24 × 3 mL cultures of YPD. The cells were grown at 28 °C, 250 rpm for 24 hours. Cells were harvested by centrifugation and resuspended in lysis buffer (50 mM of Tris-HCl, 150 mM NaCl, pH 8.0, 10% glycerol). Cells were disrupted by beads (zirconia beads from RiboPure™-Yeast Kit) for 2 min with 30 s shaking intervals on ice. The lysate was centrifuged at 4 °C, 15,000 *g* for 10 minutes to pellet cell debris.

Lysate assays were performed in 50 mM Tris-HCl, 150 mM NaCl, pH 8.0 with a final volume of 50 μL. For the assays in Fig. S17, the lysates were first desalted using a spin desalting column (Zeba, 40K MWCO). The assays contained 0–2 mM ATP, 0–10 mM MgCl₂, 5 mM L-Arg, and 5 mM Trp- d_5 . For the assays in Figure 3a, lysates with the addition of 6 mM DTT with and without 0.3 μg/mL RNase A (Qiagen) were incubated at room temperature for 20 min. RNasin (Promega) was added to the RNase treated samples at a final concentration of 20 U/mL, followed by incubation at room temperature for 5 min. The assays contained the treated lysates, 0.5 mM ATP, 10 mM MgCl₂, 5 mM L-Arg, and 5 mM Trp- d_5 , with and without 400 ng/μL of total RNA purified from yeast.⁷⁴ The reactions were incubated at room temperature for 18 hours, and an equal volume of methanol was added to quench the reactions. Samples were centrifuged and the supernatant was analyzed by QTOF as described previously.

6. Expression and purification of AnkD, AvaA, ArgRS, and TrpRS from *E. coli* BL21(DE3) and *in vitro* assays

The *ankD* gene was amplified with overhang primers from the cDNA of *A. nidulans* expressing AnkA-F. The *avaA* gene was amplified with overhang primers from the genomic DNA of *Aspergillus versicolor* dI-29. The *argRS* (YDR341C) and *trpRS* (WRS1) genes were amplified with overhang primers from the genomic DNA of *S. cerevisiae* JHY651. The expression vector pET28a was digested with NdeI/XhoI (NEB) for N-His tag expression and NcoI/XhoI (NEB) for C-His tag expression. The plasmids p3028 (N-His₆-*ankD*), p3029 (N-His₆-*avaA*), p3030 (*trpRS*-C-His₆), and p3031 (*argRS*-C-His₆) were constructed through Hifi assembly (NEB). The sequences of the assembled plasmids were confirmed by DNA sequencing.

Overexpression and subsequent protein purification of AnkD, AvaA, ArgRS, and TrpRS were performed as follows:⁷⁵ BL21(DE3) harboring the expression plasmid was grown

overnight in 16×5 mL of LB medium with $50 \mu\text{g/mL}$ of kanamycin at 37°C . The starter cultures were used to inoculate 4×1 L of fresh LB medium and shaken at 37°C until the optical density at 600 nm (OD_{600}) reached 0.8. Then expression of the gene was induced with 0.1 mM of isopropylthio- β -D-galactoside (IPTG) at 16°C . After 20 hours, cells were harvested by centrifugation, resuspended in lysis buffer (50 mM of Na_2HPO_4 , 150 mM of NaCl , 10% glycerol, $\text{pH } 8.0$), and lysed on ice by sonication. The lysate was centrifuged at $14,000\text{ g}$ for 15 min at 4°C to remove cellular debris. Purification of the recombinant His₆-tagged proteins using affinity chromatography with Ni-NTA agarose resin (Qiagen) was carried out according to the manufacturer's instructions. Purified proteins were concentrated and exchanged into storage buffer (50 mM Na_2HPO_4 , 150 mM NaCl , 10% glycerol, $\text{pH } 8.0$) by using Centriprep filters (Amicon). Purified proteins were analyzed by SDS-PAGE. Bradford Protein Assay (Bio-Rad) was used to measure protein concentration. Aliquots of purified enzymes were flash frozen and stored at -80°C . For the assays in Figure 3b, ArgRS and AvaA were further purified by FPLC with a size exclusion column (HiLoad™ 16/600 Superdex™ 75 pg) with a flow rate of 1 mL/min for 120 and 240 min, respectively, using phosphate buffer (50 mM Na_2HPO_4 , 150 mM NaCl , 10% glycerol, $\text{pH } 8.0$) as the solvent.

Enzyme assays of AnkD were performed in 50 mM Tris-HCl ($\text{pH } 8.0$) buffer with a final volume of $50\text{ }\mu\text{L}$. The assays contained $\sim 100\text{ }\mu\text{M}$ of compound **6**, $100\text{ }\mu\text{M}$ PLP, 1 mM O-acetyl homoserine, and $4\text{ }\mu\text{M}$ of purified AnkD. The reactions were incubated at room temperature for 30 min , and two volumes of methanol were added to quench the reactions. Samples were centrifuged and the supernatant was analyzed by QTOF as described previously.

For the assays in Figure 3b, total yeast RNA was deacylated by incubating $160\text{ }\mu\text{g}$ of total RNA in $50\text{ }\mu\text{L}$ of 1 M Tris ($\text{pH } 8.8$) with RNasin ($20\text{ U}/\mu\text{L}$) at 37°C for 3 hours.⁷⁶ Deacylated RNA was recovered by ethanol precipitation, and the pellet was washed with 75% ethanol before resuspension in 50 mM Na_2HPO_4 , 150 mM NaCl buffer ($\text{pH } 8.0$). Enzyme assays with AvaA were performed in 50 mM Na_2HPO_4 , 150 mM NaCl buffer with a final volume of $20\text{ }\mu\text{L}$. The assays contained 3 mM MgCl_2 , 2.5 mM ATP, 0.8 mM L-Arg, 0.8 mM Trp-d5, $400\text{ ng}/\mu\text{L}$ deacylated total yeast RNA, $0.3\text{ }\mu\text{M}$ TrpRS, $0.4\text{ }\mu\text{M}$ ArgRS, and $0.1\text{ }\mu\text{M}$ AvaA. The reactions were incubated at room temperature for 18 hours, and an equal volume of methanol was added to quench the reactions. Samples were centrifuged and the supernatant was analyzed by QTOF as described previously.

For the assays in Figure 3c, yeast tRNA was purified from yeast total RNA by neutral RNA polyacrylamide gel electrophoresis.⁷⁷ The tRNA band was cut out of the gel and crushed followed by overnight incubation in 3 volumes of 0.3 M NaCl at 4°C with constant agitation to elute the tRNA. The samples were centrifuged, and the supernatant was collected. The tRNA was recovered by ethanol precipitation, and the pellet was resuspended in 50 mM Na_2HPO_4 , 150 mM NaCl buffer ($\text{pH } 8.0$). To confirm the identity of the tRNA band, RT-PCR was performed using Superscript III (Invitrogen) and specific primers that anneal to a Trp tRNA containing an intron. The Trp tRNA cDNA product was amplified by two rounds of overhang PCR, and the spliced sequence was confirmed by Sanger sequencing. Enzyme assays with AvaA were performed in 50 mM Na_2HPO_4 , 150 mM NaCl buffer with

a final volume of 35 μ L. The assays contained 3 mM MgCl₂, 2.5 mM ATP, 0.8 mM L-Arg, 0.8 mM L-Trp, 50 ng/ μ L total yeast RNA or 16 ng/ μ L purified yeast tRNA, and 3 μ M each of purified TrpRS, ArgRS, and AvaA. The reactions were incubated at room temperature for 18 hours, and an equal volume of methanol was added to quench the reactions. Samples were centrifuged and the supernatant was analyzed by QTOF as described previously.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

This work was supported by the NIH grant R35GM118056 to Y.T. D.A.Y. is supported by the UCLA Dissertation Year Fellowship. K. N. is supported by an overseas postdoctoral fellowship from the Uehara Memorial Foundation in Japan.

References

1. Harvey AL, Edrada-Ebel R & Quinn RJ The re-emergence of natural products for drug discovery in the genomics era. *Nat. Rev. Drug Discov* 14, 111–129 (2015). [PubMed: 25614221]
2. Kenshole E, Herisse M, Michael M & Pidot SJ Natural product discovery through microbial genome mining. *Curr. Opin. Chem. Biol* 60, 47–54 (2021). [PubMed: 32853968]
3. Blin K et al. antiSMASH 5.0: updates to the secondary metabolite genome mining pipeline. *Nucleic Acids Res* 47, W81–W87 (2019). [PubMed: 31032519]
4. Khaldi N et al. SMURF: Genomic mapping of fungal secondary metabolite clusters. *Fungal Genet. Biol* 47, 736–741 (2010). [PubMed: 20554054]
5. Kautsar SA, Blin K, Shaw S, Weber T & Medema MH BiG-FAM: the biosynthetic gene cluster families database. *Nucleic Acids Res* 49, D490–D497 (2021). [PubMed: 33010170]
6. M. Gilchrist CL, Li H & Chooi Y-H Panning for gold in mould: can we increase the odds for fungal genome mining? *Org. Biomol. Chem* 16, 1620–1626 (2018). [PubMed: 29393329]
7. Biermann F & Helfrich EJM Hidden Treasures: Microbial Natural Product Biosynthesis off the Beaten Path. *mSystems* 6, e00846–21 (2021).
8. Ziemert N, Alanjary M & Weber T The evolution of genome mining in microbes – a review. *Nat. Prod. Rep* 33, 988–1005 (2016). [PubMed: 27272205]
9. Hannigan GD et al. A deep learning genome-mining strategy for biosynthetic gene cluster prediction. *Nucleic Acids Res* 47, e110 (2019). [PubMed: 31400112]
10. Barra L et al. β -NAD as a building block in natural product biosynthesis. *Nature* 600, 754–758 (2021). [PubMed: 34880494]
11. Patteson JB et al. Biosynthesis of fluopsin C, a copper-containing antibiotic from *Pseudomonas aeruginosa*. *Science* 374, 1005–1009 (2021). [PubMed: 34793213]
12. Lima ST et al. Biosynthesis of Guanitoxin Enables Global Environmental Detection in Freshwater Cyanobacteria. *J. Am. Chem. Soc* (2022) doi:10.1021/jacs.2c01424.
13. Tang MC, Zou Y, Watanabe K, Walsh CT & Tang Y Oxidative Cyclization in Natural Product Biosynthesis. *Chem. Rev* 117, 5226–5333 (2017). [PubMed: 27936626]
14. Rix U, Fischer C, Remsing LL & Rohr J Modification of post-PKS tailoring steps through combinatorial biosynthesis. *Nat. Prod. Rep* 19, 542–580 (2002). [PubMed: 12430723]
15. Du Y-L & Ryan KS Pyridoxal phosphate-dependent reactions in the biosynthesis of natural products. *Nat. Prod. Rep* 36, 430–457 (2019). [PubMed: 30183796]
16. Zhao G et al. Structural Basis for a Dual Function ATP Grasp Ligase That Installs Single and Bicyclic ω -Ester Macrocycles in a New Multicore RiPP Natural Product. *J. Am. Chem. Soc* 143, 8056–8068 (2021). [PubMed: 34028251]

17. Fawaz MV, Topper ME & Firestone SM The ATP-grasp enzymes. *Bioorganic Chem* 39, 185–191 (2011).
18. Bösch NM et al. Landornamides: Antiviral Ornithine-Containing Ribosomal Peptides Discovered through Genome Mining. *Angew. Chem* 132, 11861–11866 (2020).
19. Pan G et al. Discovery of the leinamycin family of natural products by mining actinobacterial genomes. *Proc. Natl. Acad. Sci* 114, E11131–E11140 (2017). [PubMed: 29229819]
20. Jacques IB et al. Analysis of 51 cyclodipeptide synthases reveals the basis for substrate specificity. *Nat. Chem. Biol* 11, 721–727 (2015). [PubMed: 26236937]
21. Canu N, Moutiez M, Belin P & Gondry M Cyclodipeptide synthases: a promising biotechnological tool for the synthesis of diverse 2,5-diketopiperazines. *Nat. Prod. Rep* 37, 312–321 (2020). [PubMed: 31435633]
22. Borgman P, D. Lopez R & L. Lane A The expanding spectrum of diketopiperazine natural product biosynthetic pathways containing cyclodipeptide synthases. *Org. Biomol. Chem* 17, 2305–2314 (2019). [PubMed: 30688950]
23. Chen M, Liu CT & Tang Y Discovery and Biocatalytic Application of a PLP-Dependent Amino Acid γ -Substitution Enzyme That Catalyzes C–C Bond Formation. *J. Am. Chem. Soc* 142, 10506–10515 (2020). [PubMed: 32434326]
24. Brzovic P, Holbrook EL, Greene RC & Dunn MF Reaction mechanism of *Escherichia coli* cystathionine γ -synthase: direct evidence for a pyridoxamine derivative of vinylglyoxylate as a key intermediate in pyridoxal phosphate dependent γ -elimination and γ -replacement reactions. *Biochemistry* 29, 442–451 (1990). [PubMed: 2405904]
25. Faulkner JR et al. On the Sequence of Bond Formation in Loline Alkaloid Biosynthesis. *ChemBioChem* 7, 1078–1088 (2006). [PubMed: 16755627]
26. Hai Y, Chen M, Huang A & Tang Y Biosynthesis of Mycotoxin Fusaric Acid and Application of a PLP-Dependent Enzyme for Chemoenzymatic Synthesis of Substituted l-Pipecolic Acids. *J. Am. Chem. Soc* 142, 19668–19677 (2020). [PubMed: 33155797]
27. Liu N et al. Targeted Genome Mining Reveals the Biosynthetic Gene Clusters of Natural Product CYP51 Inhibitors. *J. Am. Chem. Soc* 143, 6043–6047 (2021). [PubMed: 33857369]
28. Yee DA et al. Genome Mining of Alkaloidal Terpenoids from a Hybrid Terpene and Nonribosomal Peptide Biosynthetic Pathway. *J. Am. Chem. Soc* 142, 710–714 (2020). [PubMed: 31885262]
29. Liu N et al. Identification and Heterologous Production of a Benzoyl-Primed Tricarboxylic Acid Polyketide Intermediate from the Zaragozaic Acid A Biosynthetic Pathway. *Org. Lett* 19, 3560–3563 (2017). [PubMed: 28605916]
30. Tohyama S et al. Discovery and Characterization of NK13650s, Naturally Occurring p300-Selective Histone Acetyltransferase Inhibitors. *J. Org. Chem* 77, 9044–9052 (2012). [PubMed: 22984806]
31. Bartnik E & Weglenski P Regulation of arginine catabolism in *Aspergillus nidulans*. *Nature* 250, 590–592 (1974). [PubMed: 4602656]
32. Tsukamoto S, Kato H, Hirota H & Fusetani N Pipecolate derivatives, anthosamines A and B, inducers of larval metamorphosis in ascidians, from a marine sponge *Anthosigmella aff. raromicrosclera*. *Tetrahedron* 51, 6687–6694 (1995).
33. Kelley LA, Mezulis S, Yates CM, Wass MN & Sternberg MJE The Phyre2 web portal for protein modeling, prediction and analysis. *Nat. Protoc* 10, 845–858 (2015). [PubMed: 25950237]
34. Meister A 23. Glutamine Synthetase of Mammals. in *The Enzymes* (ed. Boyer PD) vol. 10 699–754 (Academic Press, 1974).
35. Cotton JL, Tao J & Balibar CJ Identification and Characterization of the *Staphylococcus aureus* Gene Cluster Coding for Staphyloferrin A. *Biochemistry* 48, 1025–1035 (2009). [PubMed: 19138128]
36. Challis GL A widely distributed bacterial pathway for siderophore biosynthesis independent of nonribosomal peptide synthetases. *ChemBiochem Eur. J. Chem. Biol* 6, 601–611 (2005).
37. Mydy LS, Bailey DC, Patel KD, Rice MR & Gulick AM The Siderophore Synthetase IucA of the Aerobactin Biosynthetic Pathway Uses an Ordered Mechanism. *Biochemistry* 59, 2143–2153 (2020). [PubMed: 32432457]

38. Sasaki Y, Akutsu Y, Suzuki K, Sakurada S & Kisara K Structure and analgesic activity relationship of cyclo-tyrosyl-arginyl and its three stereoisomers. *Chem. Pharm. Bull. (Tokyo)* 29, 3403–3406 (1981). [PubMed: 7337939]
39. Harvey CJB et al. HEx: A heterologous expression platform for the discovery of fungal natural products. *Sci. Adv* 15 (2018).
40. Liao HJ et al. Insights into the Desaturation of Cyclopeptin and its C3 Epimer Catalyzed by a non-Heme Iron Enzyme: Structural Characterization and Mechanism Elucidation. *Angew. Chem. Int. Ed* 57, 1831–1835 (2018).
41. Bollinger JM Jr. et al. CHAPTER 3. Mechanisms of 2-Oxoglutarate-Dependent Oxygenases: The Hydroxylation Paradigm and Beyond. in *Metallobiology* (eds. Schofield C & Hausinger R) 95–122 (Royal Society of Chemistry, 2015). doi:10.1039/9781782621959-00095.
42. Walsh CT & Wencewicz TA Flavoenzymes: Versatile Catalysts in Biosynthetic Pathways. *Nat. Prod. Rep* 30, 10.1039/c2np20069d (2013).
43. Healy FG, Krasnoff SB, Wach M, Gibson DM & Loria R Involvement of a Cytochrome P450 Monooxygenase in Thaxtomin A Biosynthesis by *Streptomyces acidiscabies*. *J. Bacteriol* 184, 2019–2029 (2002). [PubMed: 11889110]
44. Maiya S, Grundmann A, Li S-M & Turner G The Fumitremorgin Gene Cluster of *Aspergillus fumigatus*: Identification of a Gene Encoding Brevianamide F Synthetase. *ChemBioChem* 7, 1062–1069 (2006). [PubMed: 16755625]
45. Lazos O et al. Biosynthesis of the Putative Siderophore Erythrochelin Requires Unprecedented Crosstalk between Separate Nonribosomal Peptide Gene Clusters. *Chem. Biol* 17, 160–173 (2010). [PubMed: 20189106]
46. Katoh K, Rozewicki J & Yamada KD MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. *Brief. Bioinform* 20, 1160–1166 (2019). [PubMed: 28968734]
47. Izumida H, Imamura N & Sano H A Novel Chitinase Inhibitor from a Marine Bacterium, *Pseudomonas* sp. *J. Antibiot. (Tokyo)* 49, 76–80 (1996). [PubMed: 8609091]
48. Furukawa T et al. Cyclic dipeptides exhibit potency for scavenging radicals. *Bioorg. Med. Chem* 20, 2002–2009 (2012). [PubMed: 22356736]
49. Li X et al. Determination of Absolute Configuration and Conformation of a Cyclic Dipeptide by NMR and Chiral Spectroscopic Methods. *J. Phys. Chem. A* 117, 1721–1736 (2013). [PubMed: 23347158]
50. Gondry M et al. A Comprehensive Overview of the Cyclodipeptide Synthase Family Enriched with the Characterization of 32 New Enzymes. *Front. Microbiol* 9, (2018).
51. Vergne C et al. Verpacamides A–D, a Sequence of C11N5 Diketopiperazines Relating Cyclo(Pro-Pro) to Cyclo(Pro-Arg), from the Marine Sponge *Axinella vacceleti*: Possible Biogenetic Precursors of Pyrrole-2-aminoimidazole Alkaloids. *Org. Lett* 8, 2421–2424 (2006). [PubMed: 16706541]
52. Tilvi S et al. Agelastatin E, Agelastatin F, and Benzozseptrin C from the Marine Sponge *Agelas dendromorpha*. *J. Nat. Prod* 73, 720–723 (2010). [PubMed: 20166736]
53. Cusack S Aminoacyl-tRNA synthetases. *Curr. Opin. Struct. Biol* 7, 881–889 (1997). [PubMed: 9434910]
54. Ibba M & Söll D Aminoacyl-tRNA Synthesis. *Annu. Rev. Biochem* 69, 617–650 (2000). [PubMed: 10966471]
55. Gondry M et al. Cyclodipeptide synthases are a family of tRNA-dependent peptide bond-forming enzymes. *Nat. Chem. Biol* 5, 414–420 (2009). [PubMed: 19430487]
56. Moutiez M et al. Unravelling the mechanism of non-ribosomal peptide synthesis by cyclodipeptide synthases. *Nat. Commun* 5, 5141 (2014). [PubMed: 25284085]
57. Sissler M, Eriani G, Martin F, Giegé R & Florentz C Mirror Image Alternative Interaction Patterns of the Same tRNA with Either Class I Arginyl-tRNA Synthetase or Class II Aspartyl-tRNA Synthetase. *Nucleic Acids Res* 25, 4899–4906 (1997). [PubMed: 9396794]
58. John TR, Ghosh M & Johnson JD Identification and Expression of the *Saccharomyces cerevisiae* Cytoplasmic Tryptophanyl-tRNA Synthetase Gene. *Yeast* 13, 37–41 (1997). [PubMed: 9046085]

59. Jumper J et al. Highly accurate protein structure prediction with AlphaFold. *Nature* 596, 583–589 (2021). [PubMed: 34265844]
60. Moutiez M, Belin P & Gondry M Aminoacyl-tRNA-Utilizing Enzymes in Natural Product Biosynthesis. *Chem. Rev* 117, 5578–5618 (2017). [PubMed: 28060488]
61. Dyda F, Klein DC & Hickman AB GCN5-Related N-Acetyltransferases: A Structural Overview. *Annu. Rev. Biophys. Biomol. Struct* 29, 81–103 (2000). [PubMed: 10940244]
62. Ye Y et al. Fungal-derived brevianamide assembly by a stereoselective semipinacolase. *Nat. Catal* 3, 497–506 (2020). [PubMed: 32923978]
63. Li S et al. Biochemical Characterization of NotB as an FAD-Dependent Oxidase in the Biosynthesis of Notoamide Indole Alkaloids. *J. Am. Chem. Soc* 134, 788–791 (2012). [PubMed: 22188465]
64. Zou L-H et al. Copper-Catalyzed Ring-Opening/Reconstruction of Anthranils with Oxo-Compounds: Synthesis of Quinoline Derivatives. *J. Org. Chem* 84, 12301–12313 (2019). [PubMed: 31482711]
65. Arai N et al. Argadin, a New Chitinase Inhibitor, Produced by *Clonostachys* sp.FO-7314. *Chem. Pharm. Bull. (Tokyo)* 48, 1442–1446 (2000). [PubMed: 11045447]
66. Houard J et al. Cabanillasin, a new antifungal metabolite, produced by entomopathogenic *Xenorhabdus cabanillasii* JM26. *J. Antibiot. (Tokyo)* 66, 617–620 (2013). [PubMed: 23756685]
67. Garg RP, Qian XL, Alemany LB, Moran S & Parry RJ Investigations of valanimycin biosynthesis: Elucidation of the role of seryl-tRNA. *Proc. Natl. Acad. Sci* 105, 6543–6547 (2008). [PubMed: 18451033]
68. Sato M et al. Involvement of Lipocalin-like CghA in Decalin-Forming Stereoselective Intramolecular [4+2] Cycloaddition. *ChemBioChem* 16, 2294–2298 (2015). [PubMed: 26360642]
69. Yan Y et al. Resistance-gene-directed discovery of a natural-product herbicide with a new mode of action. *Nature* 559, 415–418 (2018). [PubMed: 29995859]
70. Ng LT, Pascaud A & Pascaud M Hydrochloric acid hydrolysis of proteins and determination of tryptophan by reversed-phase high-performance liquid chromatography. *Anal. Biochem* 167, 47–52 (1987). [PubMed: 3434800]
71. Ekanayake DI et al. Broomeanamides: Cyclic Octapeptides from an Isolate of the Fungicolous Ascomycete *Sphaerostilbella broomeana* from India. *J. Nat. Prod* 84, 2028–2034 (2021). [PubMed: 34191504]
72. Cacho RA & Tang Y Reconstitution of Fungal Nonribosomal Peptide Synthetases in Yeast and In Vitro. in *Nonribosomal Peptide and Polyketide Biosynthesis: Methods and Protocols* (ed. Evans BS) 103–119 (Springer, 2016). doi:10.1007/978-1-4939-3375-4_7.
73. Hang L et al. Reversible Product Release and Recapture by a Fungal Polyketide Synthase Using a Carnitine Acyltransferase Domain. *Angew. Chem* 129, 9684–9688 (2017).
74. Collart MA & Oliviero S Preparation of Yeast RNA. *Curr. Protoc. Mol. Biol* 23, 13.12.1–13.12.5 (1993).
75. Ohashi M et al. SAM-dependent enzyme-catalysed pericyclic reactions in natural product biosynthesis. *Nature* 549, 502–506 (2017). [PubMed: 28902839]
76. Janssen BD, Diner EJ & Hayes CS Analysis of aminoacyl- and peptidyl-tRNAs by gel electrophoresis. *Methods Mol. Biol. Clifton NJ* 905, 291–309 (2012).
77. Petrov A, Tsa A & Puglisi JD Chapter Sixteen - Analysis of RNA by Analytical Polyacrylamide Gel Electrophoresis. in *Methods in Enzymology* (ed. Lorsch J) vol. 530 301–313 (Academic Press, 2013). [PubMed: 24034328]




Fig 1. Reconstitution of the *ank* pathway from *A. thermomutatus* leads to new natural product.
a) The *ank* BGC encodes the PLP-dependent enzyme AnkD flanked by genes encoding potential tailoring enzymes. This gene cluster is conserved in a number of fungi as shown. Abbreviations: HP: hypothetical protein; P450: cytochrome P450 monooxygenase; FMO: flavin-dependent monooxygenase; PLP: pyridoxal-5'-phosphate dependent enzyme; NIS: NRPS-independent siderophore synthetase. No core enzyme is present, including PKS, NRPS or terpene cyclase. **b)** QTOF analysis of metabolites produced by different gene combinations in *A. nidulans* heterologous host are shown in ii) to v). The selected ions are shown and the colors of the traces match to the indicated mass and compounds. *A. nidulans* transformed with the empty vectors is the control in i). **c)** Biosynthetic pathway to **1** and **2**. The compounds indicated with “verified structure” have been fully characterized by NMR (see Supporting Information). **2** was previously reported to be a p300-selective histone acetyltransferase inhibitor.³⁰




Fig. 2. AnkaA and homologs from fungi are cyclo-arginine-Xaa-dipeptide synthases (CRDPS). MAFFT phylogenetic tree of select AnkaA homologs from sequenced fungal genomes. Six additional gene clusters encoding the analogs are shown on the right. Genes encoding AnkaA homologs (AvaA, AnoA, PthA, AteA, AmaA and EshA) are shown in red, while genes encoding putative tailoring enzymes are shown in green. The % identity and % coverage of these homologs to AnkaA are shown in parenthesis. Structures of arginine-containing cyclodipeptides synthesized by expression of the CRDPS are shown on the right.




Fig. 3. Biochemical characterization of AvaA.

a) QTOF analysis of yeast lysate containing AvaA assayed in the presence of L-Trp-(indole)-d₅. In samples treated with RNase, amino acid substrates, RNasin and total RNA were added after RNase treatment as indicated. **b**) *In vitro* assays with purified AvaA, ArgRS, TrpRS, deacylated yeast total RNA, amino acids and cofactors. Removal of any component led to loss of cyclodipeptide synthesis. The residual amount in the – Arg sample is attributed to incomplete deacylation of the total RNA sample. **c**) *In vitro* assays with purified AvaA, ArgRS, TrpRS, purified yeast tRNA, unlabeled substrates, and cofactors. **d**) Overlay of AlbC S37C mutant (brown) and AvaA model (blue) generated by AlphaFold. AlbC S37C structure (4Q24) was used because a suicide substrate analogue was co-crystallized in the enzyme active site. The dark blue and dark brown portions correspond to regions with similar structure, whereas the gray (AvaA) and beige (AlbC) correspond to regions with low similarity. The active site residues that are compared are highlighted in green. Predicted distances between the compared residues using RCSB Pairwise Structure Alignment (<http://https://www.rcsb.org/alignment>) are: AvaA C193/AlbC S37C: 2.06 Å; AvaA D428/AlbC Y202: 2.34 Å; AvaA Y392/AlbC E182: 2.58 Å. **e**) QTOF analysis of the extracts from yeast expression of wild type AvaA and C193A, C193S, and D428A mutants.




Fig. 4. Heterologous expression of *ava* tailoring enzymes from *A. versicolor* dI-29.
a) The *ava* BGC containing the RCDPS *avaA* flanked by tailoring genes. **b)** Structures of cyclo-Arg-Trp derivatives isolated from *A. nidulans* heterologous upon expression of immediate flanking genes.